Algernon Pharmaceuticals Inc.

New Therapeutic Applications for Unmet Global Medical Needs

Algernon Pharmaceuticals is a clinical-stage, Canadian drug development and repurposing company investigating drugs and naturally occurring compounds for unmet global medical needs.

About Our Company

Drug Repurposing:
An Innovative Model for Drug Development

Algernon’s drug repurposing model provides a cost-effective and capital efficient method for the discovery of new therapeutic uses for drugs that are off patent and have a well-known safety history, but have never been marketed in the U.S. or Europe. Repurposing existing, safe, small molecules to treat different disease applications requires lower capital investment, has a reduced risk of failure due to toxicity or safety issues, and usually features shorter development periods because the compounds can be moved into clinical trials more quickly than new chemical entities.

About Our Business Model

Pipeline Programs

Algernon is Advancing the Following Drugs and Compounds

Through our own research programs, and those of our new subsidiary Algernon NeuroScience, our product pipeline is currently comprised of two leading drug repurposing candidates, and a naturally occurring compound, that target a variety of medical needs.



Ifenprodil is an orally delivered small molecule that was originally developed to treat peripheral circulatory disorders. As an already approved drug in Japan with an established safety history, we are working to repurpose Ifenprodil to treat chronic cough and idiopathic pulmonary fibrosis (IPF).



Repirinast was originally an asthma drug developed by Mitsubishi Tanabe Pharma for the Japanese market. In a pre-clinical animal model of kidney fibrosis, Repirinast reduced fibrosis by 50% with statistical significance and we are working to repurpose it for chronic kidney disease through planned human trials.


(N,N-Dimethyltryptamine / DMT)

N,N-Dimethyltryptamine (DMT) is being advanced by Algernon NeuroScience, a new, wholly owned private equity subsidiary of Algernon Pharmaceuticals. DMT is a known psychedelic compound that occurs naturally in many plant species and also in many animals, including humans. DMT has been shown to induce neuroplasticity in several key preclinical studies, and we are the first in the world to investigate the drug as a potential new treatment for stroke patients and people suffering traumatic brain injury (TBI).

Learn About Our Clinical Trials

At Algernon, we conduct clinical trials as part of advancing our various drug repurposing and development programs. Please click here for study details about our current Phase 1 trial investigating DMT.

DMT Phase 1 Study Details

Stock Snapshot